What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “T3011 will be administered at a dose of 1x10\^10 PFU intravesically.”In the company’s words, NCT06971614 on ClinicalTrials.gov
- Tested for
- Nonmuscle-invasive Bladder Cancer, Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC, Advanced Melanoma and 1 more
- Main trialPhase 2
- “This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.”In the company’s words, NCT06971614 on ClinicalTrials.gov
Other drugs for Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2028 | A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC | |
| Phase 1/2Recruiting | 22 Sep 2026 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | |
| Phase 1/2Recruiting | 30 Sep 2026 | A Clinical Study of T3011 in Subjects With Advanced Melanoma | |
| Phase 1/2Recruiting | 31 Dec 2026 | A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors | |
| Phase 1/2Unknown | Jul 2023 | A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | |
| Phase 1/2Unknown | Jun 2024 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | |
| Phase 1/2Unknown | Mar 2025 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026